Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)
“Casimersen was tested in a standard battery of in vitro (bacterial reverse mutation, chromosomal aberration in CHO cells) and in vivo (mouse micronucleus) genetic toxicology assays. The studies were adequately conducted and negative.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Carcinogenicity
Not conducted pre-approval (deferred to PMR); Tg mouse and rat dose-ranging studies done
“Carcinogenicity assessments are deferred to post-marketing for the DMD indication.”
✓ VerifiedFDA pharmacology/toxicology review, p. 46Source ↗
Reproductive & developmental
Not conducted (patients extremely rare in females); male reproductive endpoints in tox studies; juvenile rat
“Reproductive and developmental toxicology studies were not required because of the intended patient population (extremely rare in females), and carcinogenicity studies may be conducted post-approval”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Safety pharmacology
Standalone monkey CV/neurological study (4 weekly IV doses up to 320 mg/kg) plus hERG; no adverse effects
“Cynomolgus monkeys received IV injections of SRP-4045 weekly for 4 total doses of 0, 5, 40, or 320 mg/kg.”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗